课题基金 / 基金详情

Clinical significance of Laminin-332 and its potential as a therapeutic target

Clinical significance of Laminin-332 and its potential as a therapeutic target
Laminin-332 的临床意义及其作为治疗靶点的潜力
批准号:
20591572
负责人:
MIYANARI Nobutomo
金额:
$3.08万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

MIYANARI Nobutomo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Inactivation of the AKT pathway by laminin-332 blocking antibody suppressed the invasiveness of esophageal cancer cell line. The addition of the purified laminin-332 activated the AKT pathway and increased the invasiveness of cell line. These results indicate that Laminin-332 could contribute to the malignant behavior of esophageal cancer through AKT pathway. mTOR is a key molecule in the AKT pathway and is increasingly important as a potential target for anticancer therapy. Thus, we focused on revealing clinical usefulness of mTOR inhibitor in esophageal cancer. p-mTOR overexpression was independently associated with poor prognosis in ESCC, supporting the potential for mTOR as a therapeutic target for ESCC. We are currently performing further in vitro and in vivo study to clarify the antitumor effect of RAD001 (mTOR inhibitor) on ESCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s00268-009-0083-6
发表时间: 2009-08-01
期刊: WORLD JOURNAL OF SURGERY
影响因子: 2.6
作者: [Ishikawa, Shinji, Shimada, Shinya, Baba, Hideo]
通讯作者: Baba, Hideo
DOI: 10.1245/s10434-010-1040-1
发表时间: 2010-09-01
期刊: ANNALS OF SURGICAL ONCOLOGY
影响因子: 3.7
作者: [Hirashima, Kotaro, Baba, Yoshifumi, Baba, Hideo]
通讯作者: Baba, Hideo
DOI: --
发表时间: 2011-03
期刊: Anticancer research
影响因子: 2
作者: [Y. Nagai;Masayuki Watanabe;S. Ishikawa;R. Karashima;J. Kurashige;S. Iwagami;M. Iwatsuki;Y. Baba;Y. Imamura;N. Hayashi;H. Baba]
通讯作者: Y. Nagai;Masayuki Watanabe;S. Ishikawa;R. Karashima;J. Kurashige;S. Iwagami;M. Iwatsuki;Y. Baba;Y. Imamura;N. Hayashi;H. Baba
Transcervical superior mediastinal lymph node dissection combined with transhiatal lower esophageal dissection before transthoracic esophagectomy: a safe approach for salvage esophagectomy.
经胸食管切除术前经颈上纵隔淋巴结清扫术联合经裂孔下食管清扫术:挽救性食管切除术的安全方法。
DOI: 10.1016/j.jamcollsurg.2009.01.018
发表时间: 2009
期刊: Journal of the American College of Surgeons
影响因子: 5.2
作者: [Masayuki Watanabe, N. Yoshida, R. Karashima, N. Sato, K. Hirashima, Y. Imamura, Y. Hiyoshi, Y. Nagai, S. Iwagami, E. Toyama, N. Hayashi, H. Baba]
通讯作者: H. Baba
21
    TET family proteins and 5-hydroxymethylcytosine in gastrointestinal carcinoma.
    • 批准号:
      26461953
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2014
    • 负责人:
      MIYANARI Nobutomo
    • 依托单位:
    Global analysis of genomic alterations associated with AKT and ERK pathway in esophageal squamous cell carcinoma
    • 批准号:
      23591941
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2011
    • 负责人:
      MIYANARI Nobutomo
    • 依托单位:
    国内基金
    海外基金
    NCAPD2通过PI3K-AKT-mTOR-Myc信号轴促进子宫内膜样癌增殖及EMT的机制与靶向治疗研究
    • 批准号:
      JCZRLH202600400
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    沉默Zdhhc23基因降低mTOR 蛋白棕榈酰化抑制黑色素瘤增殖的机制研究
    • 批准号:
      JCZRLH202601126
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    成纤维细胞中NR2F1-AS1协同KRAS通过PI3K/AKT/mTOR途径促进胰腺导管腺癌发展
    基于PI3K/Akt/mTOR信号通路介导的细胞自噬探讨参芪通痹胶囊治疗虚瘀证糖尿病周围神经病变的作用机制研究
    • 批准号:
      2026JJ81891
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      潘娟
    • 依托单位: